Antibodies to both Ro52 and Ro60 may identify Sjögren's syndrome patients best suited for clinical trials of disease-modifying therapies.

SS patients with both anti-Ro60 and Ro52 antibodies are distinguished by a higher prevalence of markers of B-cell hyperactivity and glandular inflammation. Antibody reactivity to both Ro60 and Ro52 may thus serve as an important inclusion criterion for SS patients in clinical trials where the therapeutic agent targets pathways mediating these pathogenic abnormalities.